Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Authors||Kim DG, Jin Y, Jin J, Yang H, Joo KM, Lee WS, Shim SR, Kim SW, Yoo J, Lee SH, Yoo JS, Nam DH|
|Title||Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.|
|Date||2015 Sep 1|
|Abstract Text||Vascular endothelial growth factor (VEGF) and its receptors are considered the primary cause of tumor-induced angiogenesis. Specifically, VEGFR-2/kinase insert domain receptor (KDR) is part of the major signaling pathway that plays a significant role in tumor angiogenesis, which is associated with the development of various types of tumor and metastasis. In particular, KDR is involved in tumor angiogenesis as well as cancer cell growth and survival. In this study, we evaluated the therapeutic potential of TTAC-0001, a fully human antibody against VEGFR-2/KDR. To assess the efficacy of the antibody and pharmacokinetic (PK) relationship in vivo, we tested the potency of TTAC-0001 in glioblastoma and colorectal cancer xenograft models. Antitumor activity of TTAC-0001 in preclinical models correlated with tumor growth arrest, induction of tumor cell apoptosis, and inhibition of angiogenesis. We also evaluated the combination effect of TTAC-0001 with a chemotherapeutic agent in xenograft models. We were able to determine the relationship between PK and the efficacy of TTAC-0001 through in vivo single-dose PK study. Taken together, our data suggest that targeting VEGFR-2 with TTAC-0001 could be a promising approach for cancer treatment.|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Tanibirumab||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Tanibirumab (TTAC-0001) inhibited angiogenesis and tumor growth in human cell line xenograft models of colorectal cancer (PMID: 26325365).||26325365|
|Unknown unknown||glioblastoma multiforme||not applicable||Tanibirumab||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Tanibirumab (TTAC-0001) inhibited angiogenesis and tumor growth in human glioblastoma cell line xenograft models (PMID: 26325365).||26325365|
|Unknown unknown||breast cancer||not applicable||Tanibirumab||Preclinical - Cell culture||Actionable||In a preclinical study, Tanibirumab (TTAC-0001) inhibited angiogenesis in a cell culture assay with human breast cancer cells (PMID: 26325365).||26325365|
|Unknown unknown||colorectal cancer||not applicable||Fluorouracil + Tanibirumab||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of Tanibirumab (TTAC-0001) and Adrucil (fluorouracil) demonstrated enhanced inhibition of angiogenesis and tumor growth in colorectal cancer cell line xenograft models compared to either agent alone (PMID: 26325365).||26325365|